Drug Trial Radar · NCT06884865
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Feb 26, 2025
Primary completion
Nov 2026
Study completion Jul 2032
Sponsor
- Lead sponsor
- Pacira Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is. Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse events. Researchers will also explore how PCRX-201 may impact knee pain and joint function over time. Participants will be asked to * Visit the clinic for pretreatment and drug administration * Visit the clinic for checkups and tests: 1. Screening through Week 52: intially weekly, bi-weekly, later monthly 2. Week 53 through Week 260 (Year 5): 8 visits throughout the period
Conditions
- Osteoarthritis (OA) of the Knee
Interventions
Enekinragene Inzadenovec (PCRX-201)Biological
Enekinragene Inzadenovec (PCRX-201) injection
PlaceboBiological
Placebo injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence (number and percent) of treatment-emergent adverse events (TEAEs) for PCRX-201 Dose A and Dose B versus placebo from Week 1 through Week 52Time frame: Week 1 through Week 52.
- Incidence (number and percent) of adverse events of special interest (AESIs) for PCRX-201 Dose A and Dose B versus placebo from Week 1 through Week 52Time frame: Week 1 through Week 52.
- Incidence (number and percent) of serious adverse events (SAEs) for PCRX-201 Dose A and Dose B versus placebo from Week 1 through Week 52Time frame: Week 1 through Week 52.
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Flourish Research - Birmingham
Birmingham, Alabama · Not yet recruiting
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama · Withdrawn
OrthoArizona
Phoenix, Arizona · Not yet recruiting
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix
Phoenix, Arizona · Not yet recruiting
Osteoporosis Medical Center
Beverly Hills, California · Active not recruiting
Advanced Clinical Research Center, LLC dba TriWest Research Associates, LLC
Chula Vista, California · Not yet recruiting
Medvin Clinical Research - Covina
Covina, California · Not yet recruiting
Beach Physicians Medical Group Inc.
Huntington Beach, California · Recruiting
Horizon Clinical Research
La Mesa, California · Active not recruiting
Source Healthcare
Santa Monica, California · Not yet recruiting
Alliance Clinical West Hills (Focus Clinical Research)
West Hills, California · Withdrawn
Medvin Clinical Research - Whittier
Whittier, California · Not yet recruiting
Arrow Clinical Trials
Daytona Beach, Florida · Recruiting
Journey Research Inc.
Oldsmar, Florida · Active not recruiting
Discovery Health Research Center - Plantation, FL
Plantation, Florida · Not yet recruiting
Gulfcoast Research Institute
Sarasota, Florida · Not yet recruiting
Palm Beach Research Center
West Palm Beach, Florida · Active not recruiting
Conquest Research
Winter Park, Florida · Active not recruiting
Pinnacle Trials, Inc.
Atlanta, Georgia · Not yet recruiting
Rush Medical College - Division of Rheumatology
Chicago, Illinois · Not yet recruiting
Accurate Clinical Research, Inc. - Lake Charles
Lake Charles, Louisiana · Not yet recruiting
Best Clinical Trials, LLC
New Orleans, Louisiana · Not yet recruiting
LifeBridge Health
Baltimore, Maryland · Not yet recruiting
Michigan Orthopaedic and Spine Surgeons
Rochester Hills, Michigan · Not yet recruiting
Physicians Research Collaboration
Lincoln, Nebraska · Recruiting
Excel Clinical Research
Las Vegas, Nevada · Active not recruiting
NY Scientific
Brooklyn, New York · Not yet recruiting
New York University (NYU) Center for Musculoskeletal Care
New York, New York · Not yet recruiting
West Clinical Research
Morehead City, North Carolina · Not yet recruiting
M3 Wake Research - Wilmington, NC
Wilmington, North Carolina · Not yet recruiting
META Medical Research Institute
Dayton, Ohio · Not yet recruiting
University Orthopedics Center
Altoona, Pennsylvania · Not yet recruiting
Altoona Center for Clinical Research
Duncansville, Pennsylvania · Active not recruiting
Clinical Trials of South Carolina - Charleston
Charleston, South Carolina · Active not recruiting
Clinical Trials of South Carolina - Columbia
Columbia, South Carolina · Active not recruiting
Campbell Clinic
Collierville, Tennessee · Not yet recruiting
Zenos Clinical Research
Dallas, Texas · Active not recruiting
Helios CR, Inc.
Dallas, Texas · Not yet recruiting
Accurate Clinical Research, Inc - Houston
Houston, Texas · Not yet recruiting
Epic Clinical Research
Lewisville, Texas · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.